Development of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin

Sunitinib is associated with a high incidence of hand-foot skin reaction (HFSR) that significantly affects the quality of life and treatment continuation of the patient. The relationships between the concentrations of sunitinib and its metabolites in tissues and the occurrence of HFSR are crucial to preventing it. Therefore, this study developed a quantitative method for measuring the concentrations of sunitinib and its metabolites in human nails and skin. In addition, we evaluated whether this method can be applied to measure these drug concentrations in clinical samples. Nails or skin were crushed, methanol was added, and the supernatant obtained by centrifugation was used for analysis. Sunitinib, its metabolites, and voriconazole (internal standard: IS) were analyzed using liquid chromatography/mass spectrometry with electrospray ionization in positive mode. All samples were processed in the dark, and the analysis time was 5 min/run. In nail samples, calibration curves were linear in the range of 40-2000 pg/mg for sunitinib and N-desethyl sunitinib and 4-200 pg/mg for sunitinib N-oxide. In skin samples, linearity was observed in the range of 400-6000 pg/mg for sunitinib and N-desethyl sunitinib and 8-120 pg/mg for sunitinib N-oxide. The intra- and inter-day precision and accuracy were within 15 %, with a lower limit of quantification of 20 %. Extraction recoveries were ≥ 80 %, and the coefficients of variation for the IS-normalized matrix coefficients were < 15 %. This method was successfully applied to quantify these compounds in the nails and skin of patients receiving sunitinib treatment.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical and Biomedical Analysis
Published
2025-11-09
DOI
https://doi.org/10.1016/j.jpba.2025.117242
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin

Mari Kogo, Jun Morita, Masayuki Ohbayashi, Miki Takenaka Sato et al.
Journal of Pharmaceutical and Biomedical Analysis
Chronic Myeloid Leukemia Treatments
article

Development of an LC-MS/MS method for the quantification of sunitinib and its metabolites in human nail and skin

Mari Kogo, Jun Morita, Masayuki Ohbayashi, Miki Takenaka Sato, Noriko Kohyama, Yoshiko Maeda, Hideaki Yashima, Takashi Fukagai, Y. OGAWA, Koujirou Yamamoto, Takuya Araki
article en

Abstract

Sunitinib is associated with a high incidence of hand-foot skin reaction (HFSR) that significantly affects the quality of life and treatment continuation of the patient. The relationships between the concentrations of sunitinib and its metabolites in tissues and the occurrence of HFSR are crucial to preventing it. Therefore, this study developed a quantitative method for measuring the concentrations of sunitinib and its metabolites in human nails and skin. In addition, we evaluated whether this method can be applied to measure these drug concentrations in clinical samples. Nails or skin were crushed, methanol was added, and the supernatant obtained by centrifugation was used for analysis. Sunitinib, its metabolites, and voriconazole (internal standard: IS) were analyzed using liquid chromatography/mass spectrometry with electrospray ionization in positive mode. All samples were processed in the dark, and the analysis time was 5 min/run. In nail samples, calibration curves were linear in the range of 40-2000 pg/mg for sunitinib and N-desethyl sunitinib and 4-200 pg/mg for sunitinib N-oxide. In skin samples, linearity was observed in the range of 400-6000 pg/mg for sunitinib and N-desethyl sunitinib and 8-120 pg/mg for sunitinib N-oxide. The intra- and inter-day precision and accuracy were within 15 %, with a lower limit of quantification of 20 %. Extraction recoveries were ≥ 80 %, and the coefficients of variation for the IS-normalized matrix coefficients were < 15 %. This method was successfully applied to quantify these compounds in the nails and skin of patients receiving sunitinib treatment.

Journal of Pharmaceutical and Biomedical AnalysisVol. 269
SHOWA Medical University (JP), Gunma University (JP), SHOWA Medical University Hospital (JP), Showa Pharmaceutical University (JP)
Openalex Percentile: Top 55%
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.